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Background. The Joint United Nations Programme on HIV/AIDS (UNAIDS) has set a “90-90-90” target to curb the human 
immunodeficiency virus (HIV) epidemic by 2020, but methods used to assess whether countries have reached this target are not 
standardized, hindering comparisons.
Methods. Through a collaboration formed by the European Centre for Disease Prevention and Control (ECDC) with European 
HIV cohorts and surveillance agencies, we constructed a standardized, 4-stage continuum of HIV care for 11 European Union coun-
tries for 2013. Stages were defined as (1) number of people living with HIV in the country by end of 2013; (2) proportion of stage 1 
ever diagnosed; (3) proportion of stage 2 that ever initiated ART; and (4) proportion of stage 3 who became virally suppressed (≤200 
copies/mL). Case surveillance data were used primarily to derive stages 1 (using back-calculation models) and 2, and cohort data 
for stages 3 and 4.
Results. In 2013, 674 500 people in the 11 countries were estimated to be living with HIV, ranging from 5500 to 153 400 in each 
country. Overall HIV prevalence was 0.22% (range, 0.09%–0.36%). Overall proportions of each previous stage were 84% diagnosed, 
84% on ART, and 85% virally suppressed (60% of people living with HIV). Two countries achieved ≥90% for all stages, and more 
than half had reached ≥90% for at least 1 stage.
Conclusions. European Union countries are nearing the 90-90-90 target. Reducing the proportion undiagnosed remains the 
greatest barrier to achieving this target, suggesting that further efforts are needed to improve HIV testing rates. Standardizing meth-
ods to derive comparable continuums of care remains a challenge.
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The human immunodeficiency virus (HIV) continuum of 
care is a public health monitoring tool to conceptualize the 
care pathway that people living with HIV (PLHIV) progress 
through: diagnosis of HIV infection, linkage to and retention 
in HIV care, initiation of and adherence to antiretroviral ther-
apy (ART), and suppression of viremia [1]. This concept has 
increasingly been adopted to evaluate HIV program perfor-
mance. Four stages of the HIV continuum can also be used to 
monitor the Joint United Nations Programme on HIV/AIDS 
(UNAIDS) “90-90-90” target (90% of PLHIV diagnosed, 90% 
of those diagnosed on ART, 90% of those on treatment virally 
suppressed), which aims to curb the HIV epidemic by 2020 [2].
However, challenges with data quality, appropriate data 
sources, and the absence of standardized definitions have ham-
pered comparisons across countries. An initiative led by the 
European Centre for Disease Prevention and Control (ECDC) 
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in 2014 to monitor the Dublin Declaration on Partnership to 
Fight HIV/AIDS in Europe and Central Asia identified that 
many European countries lacked data for some, or all, con-
tinuum stages [3, 4]. This study, as well as a recent systematic 
review, concluded that, although many continuum estimates are 
being published, their comparability is limited by differences in 
data sources and methods used [3, 5].
Collaborations between public health surveillance and 
national clinical cohorts, where the latter exist, could help 
address gaps in data availability. The key advantage of using lon-
gitudinal clinical cohort data lies in their potential to enhance 
the internal consistency of care continuums by using the same 
group of individuals, defined as “denominator-denominator 
linkage” [6], to analyze multiple stages. While the ideal contin-
uum will maximize the number of stages with denominator-de-
nominator linkage, additional data from HIV case surveillance 
systems are necessarily required to provide information on the 
diagnosed population, and as modeling inputs to estimate the 
total number of PLHIV.
We, therefore, aimed to construct a 4-stage standardized 
continuum of HIV care for 11 European countries using HIV 
case surveillance and national clinical cohort data. We assess 
the utility of using cohort data and describe the challenges 
encountered.
METHODS
Selection of Countries and Cohorts
HIV cohorts were drawn from EuroCoord (www.EuroCoord.
net), a European Union (EU)–funded Network of Excellence 
that includes most European HIV cohorts [7, 8]. Only cohorts 
considered national—that is, multicenter and not restricted by 
risk group—were included. HIV cohorts and surveillance agen-
cies in Austria, Belgium, Denmark, France, Germany, Greece, 
Italy, the Netherlands, Spain, Sweden, and the United Kingdom 
took part (Supplementary Data 1).
Standardized Definitions and Data Sources
Continuums of HIV care were constructed for each country 
using national-level HIV case surveillance data and HIV clin-
ical cohort data. Four stages of the continuum of HIV care 
were estimated for 2013, the most recent year of data available 
(Table 1).
Stage 1: Number of PLHIV
Stage 1 was defined as the estimated total number of PLHIV in 
each country by the end of 2013. Those who had died or out-mi-
grated were excluded where possible. Several countries had no 
out-migration data or could only make assumptions about the 
proportion who out-migrated (Supplementary Data 2).
Where feasible, back-calculation models that estimate HIV 
incidence and the undiagnosed fraction from routinely col-
lected HIV case surveillance data were used. For consistency, 
PLHIV estimates generated using a back-calculation modeling 
tool developed by the ECDC [9] were prioritized. Five coun-
tries used the ECDC Modelling Tool “incidence method” [10]. 
If this was not appropriate (eg, due to incomplete case surveil-
lance data), similar back-calculation methods tailored to coun-
tries’ own data were used (4 countries), either to estimate the 
Table 1. Standardized Definitions Used to Estimate the Human Immunodeficiency Virus Continuum of Care
Stage Definition Data Source Analysis and Estimation Approaches
(1) People living with 
HIV
Number of people living with HIV (diag-
nosed and undiagnosed) in each country 
by the end of 2013
HIV case surveillance 
data if available, or 
cohort data otherwise
Back-calculation models to estimate HIV incidence and the undiagnosed 
fraction (ECDC HIV Modelling Tool [9], 5 countriesa; other models, 4 
countriesb), otherwise Multi-Parameter Evidence Synthesis (United 
Kingdom), or other surveillance/survey-based estimates (Sweden).
(2) Diagnosed Proportion of (1) ever diagnosed HIV case surveillance 
data if available, or 
cohort data otherwise
Cumulative number of diagnosed by end of 2013, excluding out-mi-
grations and deaths before the end of 2013 if feasible (3 countriesc 
using surveillance data, 3 countriesd using national cohort data). 
Otherwise, the diagnosed population was estimated using: 
ECDC HIV Modelling Tool (Austria, Belgium), statistical modeling 
(Spain), combining estimates of the population in care/ not in care 
(France), or clinic-based surveys (Italy).
(3) ART Proportion of (2) who ever initiated ART 
(regardless of treatment guidelines, 
antiretroviral drug regimens or number 
of drugs, treatment interruptions, or 
discontinuations)
Country-specific HIV 
cohorts
Descriptive statistics. Patients lost to follow-up to the cohort (ART/ 
viral load status unknown) were excluded to give a high esti-
mate, and included (assumed never on ART, where ART status 
unknown) in the low estimate. The preferred estimate was taken 
as the midpoint.
(4) Virally 
suppressed
Proportion of (3) who were virally sup-
pressed (≤200 copies/mL or below the 
level of detection of the assay) at last 
visit (1 July 2012 to 31 December 2013)e
Country-specific HIV 
cohorts
As above. Patients lost to follow-up to the cohort with no recent viral 
load measurements were assumed to be unsuppressed in the 
low estimate.
Abbreviations: ART, antiretroviral therapy; ECDC, European Centre for Disease Prevention and Control; HIV, human immunodeficiency virus.
aAustria, Belgium, Denmark, Greece, the Netherlands.
bFrance, Germany, Italy, Spain.
cGermany, Greece, United Kingdom.
dDenmark, the Netherlands, Sweden.
eSix months of 2012 were included to allow for delays in updating cohort records.
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total number of PLHIV directly, or to estimate the undiagnosed 
population, combined with surveillance or survey-based esti-
mates of the diagnosed population [11–13]. Otherwise, alter-
native approaches included multiparameter evidence synthesis 
incorporating case surveillance and prevalence survey data (1 
country) [14], or surveillance/survey-based estimates (1 coun-
try) (Supplementary Data 2).
Where feasible, 95% confidence intervals (CIs) were calcu-
lated using bootstrapping techniques. Adult prevalence was cal-
culated using Eurostat population denominators for 2013 [15], 
excluding children <15 years.
Stage 2: Proportion Diagnosed
Stage 2 was defined as the proportion of all PLHIV, estimated 
as above, ever diagnosed, excluding deaths and out-migrations 
(Supplementary Data 2).
Ideally, the diagnosed population was derived from cumu-
lative HIV case surveillance data to the end of 2013 (3 coun-
tries). Where this was not feasible (eg, surveillance systems that 
started recently or changed over time in geographic coverage), 
alternative approaches were used. These included estimating 
the diagnosed fraction from the ECDC HIV Modelling Tool (2 
countries); combining estimates of the diagnosed population in 
care and not in care by triangulating data sources (1 country) 
[16]; use of national cohort data—that is, the number of patients 
diagnosed and in care, where linkage to care is expected to be 
extremely high (3 countries); statistical modeling using recent 
HIV case surveillance data to estimate new HIV diagnoses for 
all years (1 country); or infectious disease clinic survey-based 
estimates (1 country) [17].
A range of uncertainty was calculated by dividing the number 
diagnosed by the lower/upper confidence limits for the number 
of PLHIV, to reflect the uncertainty in estimating stage 1.
Stage 3: Proportion on ART
Stage 3 was defined as the proportion of those diagnosed, as 
above, who have ever initiated ART, regardless of prevailing 
treatment guidelines, antiretroviral regimens or number of 
drugs, or treatment interruptions or discontinuations. This 
definition was applied to country-specific cohort datasets. 
Patients known to have died or out-migrated by the end of 2013 
were excluded, as were patients with unknown year of diagnosis 
if it was unclear they were diagnosed before the end of 2013. 
Those with unknown ART status or unknown year of ART ini-
tiation were assumed to be untreated by the end of 2013.
Minimum and maximum estimates were calculated based 
on assumptions about patients lost to follow-up (LTFU) to 
the cohort and whether they were likely to be receiving care in 
noncohort centers, or lost to care entirely and, therefore, likely 
not on ART and unsuppressed. For the maximum estimate, 
patients LTFU were excluded, and for the minimum estimate 
they were included and assumed to be untreated, unless their 
records indicated ART initiation. LTFU was defined as no clinic 
interaction 1 July 2012–31 December 2013 and, therefore, no 
ART or viral load (VL) data. Clinic interaction was based on 
any laboratory measurement, drug start date, or other evidence 
of an HIV clinic visit. The preferred estimate was the midpoint 
between the minimum and maximum estimate.
Stage 4: Proportion Virally Suppressed
Stage 4 was defined as the proportion of those ever on ART, as 
above, with a VL measurement ≤200 HIV RNA copies/mL, or 
below the assay detection limit, at their last visit 1 July 2012–31 
December 2013. This VL threshold was chosen to allow for 
improvements over time in the lower limit of detection of the 
assay. Cohort data were used to calculate minimum and max-
imum estimates, and the midpoint between the 2.  Patients 
LTFU (ie, no recent VL measurements) were excluded for the 
maximum estimate and included for the minimum estimate 
(assumed to be unsuppressed). Patients with no VL measure-
ments 1 July 2012–31 December 2013, but classified as engaged 
in care based on other laboratory measurements, drug start 
dates, or clinic visits were assumed to be adherent to ART and 
suppressed.
Construction of Combined Regional Estimates
Country-level results were compiled and combined, and 
weighted averages calculated for each stage to construct a 
summary continuum for the region based on all 11 countries 
(Supplementary Data 3). Percentages were calculated using 
the previous stage as the denominator, as well as using a single 
denominator of PLHIV.
Ethical Approval
All participating clinical cohorts obtained ethics approvals 
from local ethics committees, national data agencies, or institu-
tional review boards. Informed consent of patients was sought 
in accordance with national regulations. Surveillance data are 
collected under the authority of the public health agencies that 
abide with strict confidentiality and privacy data protection 
laws.
RESULTS
Continuum of HIV Care Estimates by Country
National estimates for the total number of PLHIV by the end 
of 2013 ranged from 5500 in Denmark to 153 400 in France, 
corresponding to a prevalence of 0.12% and 0.29%, respectively 
(Table 2). Prevalence was lowest in Austria and Sweden (both 
0.09%), and highest in Spain (0.36%).
There was variation across the countries in the proportions 
estimated for each stage. In 2013, of all PLHIV, the proportions 
diagnosed ranged from 78% in Greece to 91% in Denmark, with 
2 other countries (Italy and Sweden) also reaching ≥90%, and 
Austria just below this threshold at 88%. Of those diagnosed, 
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the proportions on ART range from 76% in Spain to 96% in 
Belgium. Five other countries (Austria, Denmark, France, the 
Netherlands, and Sweden) achieved ≥90% on ART. There was 
less variation between countries in the proportions virally sup-
pressed. Of those on ART, the proportions virally suppressed 
were ≥81% in all countries, with the highest proportion esti-
mated at 93% in both Denmark and Sweden. France and the 
Netherlands also achieved ≥90% virally suppressed. Only 2 
countries, Denmark and Sweden, achieved ≥90% for each of the 
3 continuum stages using our standardized definitions. Of the 
total PLHIV, Denmark and Sweden reached ≥73% virally sup-
pressed, with France and the Netherlands nearing this target, at 
72% and 70%, respectively.
Combined Estimates for the European Region (11 EU Countries)
Overall, 674 500 people were estimated to be living with HIV in 
the 11 EU countries by the end of 2013 (prevalence = 0.22%). 
Overall, the proportions at each stage were 84% of PLHIV diag-
nosed (79%–90%); 84% of those diagnosed on ART (81%–87%); 
and 85% of those on ART with viral suppression (76%–91%) 
(Figure 1). Of the total PLHIV, 60% were estimated to be virally 
suppressed. The greatest drop between successive stages of the 
continuum was observed between the number of PLHIV and 
the number diagnosed, with 16% of undiagnosed individuals 
falling out of the continuum.
DISCUSSION
The 11 EU countries included in this study, constituting 
roughly three-quarters of the EU population and three-quar-
ters of HIV diagnoses in the EU in 2005–2014 [18], are nearing 
the UNAIDS 90-90-90 target, well ahead of 2020. Although few 
Figure 1. Continuum of human immunodeficiency virus (HIV) care in 11 European 
Union countries (Austria, Belgium, Denmark, France, Germany, Greece, Italy, The 
Netherlands, Spain, Sweden, and United Kingdom) for 2013. Weighted averages, 
accounting for the number of HIV-infected individuals at each stage in each coun-
try, were taken across all countries for each stage.*Percentages out of the previ-
ous stage. **Percentages among all people living with HIV by the end of 2013. 
Abbreviations: ART, antiretroviral therapy; PLHIV, people living with human immu-
nodeficiency virus; VL, viral load.
Table 2. Estimates for 4 Stages of the Human Immunodeficiency Virus Continuum of Care for 2013, by Country
Country (1) No. PLHIV (95% CI) HIV Prevalencea
(2) Diagnosed 
(Estimated Range)b
(3) Ever on 
ART (Min, Max 
Estimate)
(4) Suppressed  
(Min, Max Estimate)
Suppressed of All 
PLHIV
Austria  6500 (6300–6700)c 0.09% 88% (86%–91%) 90% (85%, 94%) 84% (76%, 91%) 66%
Belgium 18 000 (17 700–18 300) 0.19% 84% (83%–85%) 96% (96%, 96%) 82% (77%, 87%) 66%
Denmark 5500 (5000–6000)d 0.12% 91% (83%–100%) 94% (93%, 94%) 93% (93%, 93%) 80%
France 153 400 (150 600–155 900) 0.29% 84% (82%–85%) 93%e 92%e 72%
Germany 80 000 (69 000–91 000) 0.11% 83% (73%–96%) 87% (83%, 90%) 81% (69%, 92%) 58%
Greece 14 200 (13 700–14 600) 0.15% 78% (76%–81%) 82% (79%, 84%) 81% (72%, 89%) 52%
Italy 128 100 (122 400–133 500)f 0.25% 90% (86%–94%) 80% (75%, 85%) 82% (74%, 90%) 59%
The Netherlands 22 000 (21 400–22 800) 0.16% 85% (82%–88%) 91% (90%, 92%) 91% (88%, 94%) 70%
Spain 140 700 (128 200–155 200) 0.36% 82% (78%–86%)g 76% (73%, 78%) 81% (72%, 89%) 50%
Sweden 7000h 0.09% 90%h 92% (92%, 92%) 93% (93%, 93%) 77%
United Kingdom 99 100 (93 000–107 400) 0.19% 81% (75%–87%)i 82% (76%, 88%) 82% (70%, 94%) 54%
Percentages shown for stages 2, 3, and 4 are out of the previous stage. Percentages in the final column are calculated out of the total PLHIV (1). Estimates were constructed using stan-
dardized methods and may differ from previously published results and official national statistics due to differences in data sources, definitions, and time periods [20–24].
Abbreviations: ART, antiretroviral therapy; CI, confidence interval; HIV, human immunodeficiency virus; PLHIV, people living with human immunodeficiency virus.
aAdult HIV prevalence was estimated by dividing the number of PLHIV by Eurostat population denominators for adults aged ≥15 years in 2013.
bEstimated ranges for the percentage diagnosed were calculated by dividing the number diagnosed by the upper and lower confidence limits for stage 1 (PLHIV), to reflect the uncertainty 
in the estimate for stage 1, unless otherwise indicated.
cEstimate for PLHIV generated using Austrian cohort data, which cover approximately 76% of people living with HIV in Austria.
dEstimated range (CI not available), informed by the ECDC Modelling Tool and triangulation with other estimates.
eMinimum estimates are not applicable due to the methodology and data sources used to derive the population in care in France. Upper estimates were used to substitute the (missing) 
minimum estimates when calculating the combined estimates for the proportion on ART and proportion virally suppressed in the 11 European Union countries.
fRange for PLHIV in Italy calculated using the 95% CI for the undiagnosed estimate and, separately, a range of uncertainty for the number diagnosed and lost from care.
gThe 95% CI, reflecting the uncertainty in estimating the diagnosed population nationally in Spain, using a statistical model.
hSurveillance and survey-based estimate for PLHIV; CIs were therefore not available for the estimate of PLHIV, nor was a range available for the diagnosed estimate. However, in Sweden, 
the number diagnosed is reliably estimated from the national cohort and surveillance data, for which there is no under- or delayed reporting. Point estimate of 7000 PLHIV used to substitute 
the (missing) upper and lower limit when calculating the overall range for the percentage diagnosed in the 11 European Union countries combined.
iAbsolute number diagnosed in the United Kingdom is reliably derived from national surveillance data. The range presented reflects the uncertainty in the estimate for stage 1.
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countries achieved ≥90% for each stage, based on our stand-
ardized definitions, more than half had reached, or were close 
to, the target for at least 1 stage. Further improvements are also 
expected to have occurred since 2013, following recent changes 
in treatment guidelines [19]. However, reducing the undiag-
nosed proportion remains the biggest barrier to achieving this 
goal, with the largest drop between successive stages of the con-
tinuum observed at this first stage. To our knowledge, this is the 
first attempt to standardize definitions and derive continuum of 
care estimates for the EU. Our estimates may differ from previ-
ously published results and official national statistics due to dif-
ferences in data sources, definitions, and time periods, although 
these differences are relatively minor [20–25].
UNAIDS estimates for the number of PLHIV in 2013, 
derived using Spectrum/EPP software with HIV prevalence 
data and most suitable for countries with generalized epidemics 
[26], were only reported for 4 of the countries in our study [27]. 
Our estimates, based primarily on back-calculation modeling 
and routinely collected HIV case surveillance data, strengthen 
data availability for this stage and provide valuable informa-
tion for HIV program monitoring and planning. We observed 
the highest HIV burden in France, Spain, Italy, and the United 
Kingdom, accounting for the majority of PLHIV in this region, 
concurring with earlier reports [27].
Losses from the continuum occurred between all stages, but 
were greatest between stages 1 and 2. Overall, 16% of PLHIV 
were undiagnosed, indicating that further efforts are required 
to improve HIV testing rates, particularly among most at-risk 
populations. Late presentation remains a major concern in 
Europe, with around half of new diagnoses presenting with a 
CD4 count <350 cells/µL [18, 28]. A  systematic review pub-
lished in 2011 suggested that rapid testing and counseling in 
community settings, community-based peer counseling cam-
paigns, and expansion of opt-out testing policies may be effec-
tive interventions to improve HIV testing rates in men who have 
sex with men in high-income countries [29]. Provision of rapid 
HIV tests in pharmacies [30], and provider-initiated HIV test-
ing in general practice or individuals presenting with indicator 
conditions [31, 32], may offer further opportunities to increase 
testing uptake. Widening legislation for and increasing access to 
self-testing and self-sampling are likely to increase testing, but 
must be coupled with channels for linkage to care [21].
The lowest proportions of diagnosed individuals on ART 
were estimated in Spain, Italy, Greece, and the United Kingdom. 
National treatment guidelines are likely to play a key role here. 
For example, in 2013, treatment guidelines in Greece, Spain, 
and the United Kingdom recommended ART initiation in 
patients with CD4 counts of ≤350 cells/µL. The proportion on 
ART is expected to improve once the recent changes in guide-
lines [19] are implemented. Lack of, or delayed, linkage to care 
following HIV diagnosis is a possible explanation. Although 
patients in high-income countries are usually linked to care 
within 3 months of diagnosis, delays among specific subgroups 
have been reported [16, 33]. Failure to achieve viral suppression 
after starting ART may reflect poor adherence, treatment inter-
ruptions or discontinuations, or insufficient time to achieve 
suppression for those recently initiating ART [16].
Increasing awareness of the continuum of care—for exam-
ple, through national treatment and/or service delivery guide-
lines—and providing evidence-based recommendations to 
improve the testing and care environment, may also improve 
the care continuum [34].
These results must be interpreted in light of several key meth-
odological challenges encountered. Use of the HIV Modelling 
Tool [9] facilitated the standardization of estimates for PLHIV, 
but applying the same approach to countries with different HIV 
surveillance systems was not always possible due to insufficient 
historical case surveillance data availability in some countries. 
Triangulation of data sources provides one possible solution, 
for example, summing estimates of the undiagnosed population 
with cohort or survey-based estimates of the diagnosed popula-
tion in care/not in care [12].
Difficulties capturing out-migration or linking surveillance 
or cohort datasets to population migration and death registries 
were additional challenges. Misclassification of vital status or 
out-migration will potentially overestimate the number still 
alive and living in a country. Few countries in our study had 
access to reliable out-migration data (Supplementary Data 2), 
with linkage to population registries usually precluded by the 
lack of unique identifiers. Where possible, adjustments were 
made using estimated levels of out-migration. In the long term, 
efforts to improve the recording of vital status and out-migra-
tion in surveillance databases, as well as linkage to registries via 
unique identifiers, are needed. In some cases, lack of reliable 
in-migration data also complicated modeling of HIV incidence 
and the separating of earlier infections from new infections 
occurring after arrival within the country.
Estimating proportions using cohorts that are not representa-
tive of the diagnosed population nationally may introduce bias, 
so efforts are required to understand and correct for this. The 
cohorts in our study were large, including national cohorts with 
near complete coverage of the diagnosed population, and were 
fairly representative (Supplementary Data 1) [35]. Nevertheless, 
estimates from cohorts with low coverage should be interpreted 
with caution. Ideally, estimates derived using cohort data would 
be adjusted by calculating and applying weights based on the 
distribution of demographic variables in cohort and surveil-
lance datasets [35].
Patients LTFU in cohort data present another challenge—
namely, the assumptions that are made about whether they are 
still in care, taking ART and virally suppressed, or truly lost 
from care and unsuppressed. Assuming all have been lost from 
care entirely would underestimate retention in care and the 
proportion suppressed, as suggested by a clinical audit in the 
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United Kingdom [36]. Ideally cohorts would collect and update 
data on patients who transfer to other clinics, although this is 
challenging in practice. In the absence of reliable patient trans-
fer data, plausible limits should be calculated based on varying 
assumptions, as we have done, with the true value likely to lie 
between these limits.
There were several strengths and limitations to this study. 
Collaborations formed between cohort investigators and surveil-
lance agencies facilitated the construction of HIV continuums from 
PLHIV to viral suppression. We attempted to standardize methods 
to enhance comparability between countries, and to generate sum-
mary estimates for the region. However, complete standardization 
was not possible, given the different limitations in data availability 
and quality in each country, as well as inherent differences in cohort 
inclusion criteria. For example, the Italian and Spanish cohorts 
require participants to be ART-naive at baseline (Supplementary 
Data 1). Although the use of cohort data improved the internal 
consistency of the estimates, we were unable to link surveillance 
and cohort datasets in most countries to maximize internal con-
sistency. For some countries we were unable to distinguish between 
those diagnosed and those linked to care (ie, enrolled in a cohort), 
although linkage to care is expected to be very high.
Additionally, our cross-sectional definitions do not address 
the timeliness of reaching each stage, or time spent at each 
stage, for example, time since starting ART [16]. Using a single 
VL measurement may also overestimate durable viral suppres-
sion [37]. However, our definitions provide a snapshot of the 
continuum in 2013 that is simple to interpret and communicate 
to policy makers. Treatment discontinuations or interruptions 
were not accounted for, which may result in overestimating the 
proportion “on ART.” However, a sensitivity analysis conducted 
for a few countries, restricting the definition of “on ART” to 
a record of ART between 1 July 2012 and 31 December 2013, 
made little difference to the overall proportions of PLHIV who 
were virally suppressed.
Finally, our study omitted 17 EU countries, mainly from 
Eastern and Central Europe as national cohort data were lack-
ing, and, as such, estimates for the whole EU region may be 
lower than those presented here.
CONCLUSIONS
The 11 EU countries in our study are nearing the UNAIDS 
90-90-90 target, with more than half having achieved ≥90% 
for 1 or more stages of the continuum. The main barrier to 
achieving this goal appears to be reducing the proportion 
undiagnosed. These data provide useful comparisons to gov-
ernments and healthcare planners, but must be interpreted 
in context of the limitations and key challenges above, as well 
as cohort and country differences. Challenges remain in con-
structing and standardizing the continuum of care for all stages. 
Enhancements to data sources and methods are required to 
derive accurate estimates for national-level continuums of care, 
to facilitate comparisons between countries, and to generate 
regional and global estimates.
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APPENDIX
Austrian HIV Cohort Study, Austria:
Steering committee members: Ninon Taylor, Maria Geit, 
Bernhard Haas, Manfred Kanatschnig, Armin Rieger, Andrea 
Steuer, Robert Zangerle
Coordinating Centre: University Hospital Innsbruck (Robert 
Zangerle)
Funding: Austrian Agency for Health and Food Safety 
(AGES), Hospitals running HIV treatment centres, pharma-
ceutical companies (equal contributions, irrespective of their 
market shares)
HIV treatment centres (*site coordinating physicians): LKH 
Innsbruck: Martin Gisinger, Maria Kitchen, Alexander Plattner, 
Elisabeth Rieser, Mario Sarcletti*, Robert Zangerle. LKH 
Salzburg: Alexander Egle, Richard Greil*, Michaela Schachner, 
Ninon Taylor. Kepler Universitätsklinikum Med Campus 
III. Linz: Maria Geit*, Angela Öllinger. AKH Vienna: Regina 
Aichwalder, Katharina Grabmeier-Pfistershammer, Armin 
Rieger*, Veronique Touzeau. Otto-Wagner Hospital Vienna: 
Piotr Cichon, Manfred Gartner, Brigitte Schmied, Andrea 
Steuer*. Kaiser-Franz-Josef Hospital Vienna: Hermann Laferl, 
Alexander Zoufaly*. LKH Graz Süd-West: Bernhard Haas*, 
Andreas Kapper, Elmar Wallner. LKH Klagenfurt: Manfred 
Kanatschnig*, Georg Schober.
HIV Continuum of Care in the European Union • CID 2017:64 (15 June) • 1651
Virology: Elisabeth Puchhammer-Stöckl (Vienna), Jörg Berg 
(Kepler Universitäts-klinikum Med Campus III, Linz).
Data management: Heinz Appoyer (IT-related), Gisela 
Leierer (AHIVCOS), Michaela Rappold (AHIVCOS), Stefanie 
Strickner (AHIVCOS).
Data safety and protection: Klaus Schindelwig (Innsbruck).
Scientific advisory board: Bruno Ledergerber (Zurich), Gerd 
Fätkenheuer (Cologne).
Belgian HIV cohort, Belgium:
The Belgian HIV surveillance including the Belgian HIV cohort 
is coordinated by the WIV/ISP (Scientific Institute of Public 
Health) and financed by the Belgian National Institute for 
Sickness and Invalidity Insurance (INAMI/RIZIV).
The WIV-ISP thanks the following members of the Belgian 
Research on AIDS and HIV Consortium (BREACH) for provid-
ing the data: S. De Wit (ARC CHU Saint-Pierre), M.-L. Delforge 
(ARL Hôpital Erasme), E. Florence (ARC ITG), K. Fransen (ARL 
ITG), J.-C. Goffard (ARC Hôpital Erasme), M.-P. Hayette (ARL 
CHU Liège), P. Lacor (ARC UZ Brussel), R. Demeester (ARC 
CHU Charleroi), M. Moutschen (ARC CHU Liège), D. Piérard 
(ARL UZ Brussel), J. Ruelle (ARL UCL), D. Vaira (ARL CHU 
Liège), L. Vandekerckhove (ARC UZ Gent), S. Van den Wijngaert 
(ARL Hôpital Saint-Pierre), B. Vandercam (ARC Cliniques 
Universitaires Saint-Luc), M. Van Ranst (ARL KUL), E. Van 
Wijngaerden (ARC UZ Leuven), C. Verhofstede (ARL UZ Gent).
Danish HIV Cohort Study, Denmark:
This work was supported by Preben og Anne Simonsens 
Foundation.
The Danish HIV Cohort Study includes patients from the 
Departments of Infectious Diseases at Copenhagen University 
Hospitals, Rigshospitalet (J. Gerstoft, N.  Obel) and Hvidovre 
(G. Kronborg), Odense University Hospital (C. Pedersen), 
Aarhus University Hospitals, Skejby (C.S. Larsen) and Aalborg 
(G. Pedersen), Herning Hospital (R Mohey), Hillerød Hospital 
(L. Nielsen), Roskilde Hospital (L Weise), Herlev University 
Hospital (B Kvinesdal) and Kolding Hospital (J. Jensen).
FHDH-ANRS CO4 cohort, France:
The FHDH ANRS CO4 cohort is funded by the ANRS, INSERM 
and the French Ministry of Health.
• Scientific committee: S Abgrall, L Bernard, E Billaud, F 
Boué, L Boyer, A Cabié, F Caby, A Canestri, D Costagliola, 
L Cotte, P De Truchis, X Duval, C Duvivier, P Enel, H 
Fischer, J Gasnault, C Gaud, S Grabar, MA Khuong, O 
Launay, L Marchand, M Mary-Krause, S Matheron, G 
Melica-Grégoire, H Melliez, JL Meynard, M Nacher, J 
Pavie, L Piroth, I  Poizot-Martin, C Pradier, J Reynes, E 
Rouveix, A Simon, L Slama, P Tattevin, H Tissot-Dupont.
• COREVIH coordinating center: French Ministry of Health 
(G Astier, J Biga, T Kurth, I Prade), Technical Hospitalization 
Information Agency, ATIH (N Jacquemet).
• Statistical analysis center: UMRS 1136 INSERM et UPMC 
(D Costagliola, Principal investigator, S Abgrall, S Grabar, 
M Guiguet, S Lang, L Lièvre, M Mary-Krause, H Roul, H 
Selinger-Leneman), INSERM-Transfert (V Potard).
• COREVIH: Paris area: Corevih Ile de France Centre 
(Paris-GH Pitié Salpétrière: O Benveniste, A  Simon, G 
Breton, C Lupin, E Bourzam; Paris-Hôpital Saint-Antoine: 
PM Girard, L Fonquernie, N Valin, B Lefebvre, M Sebire; 
Paris-Hôpital Tenon: G Pialoux, MG Lebrette, P Thibaut, 
A  Adda, M Hamidi, J Cadranel, A  Lavolé, A  Parrot), 
Corevih Ile de France Est (Bobigny-Hôpital Avicenne: O 
Bouchaud, N Vignier, F Méchaï, S Makhloufi, P Honoré; 
Bondy-Hôpital Jean Verdier; Paris-GH Lariboisière-
Fernand Widal: JF Bergmann, V Delcey, A Lopes, P Sellier, 
M Parrinello Paris-Hôpital Saint-Louis: E Oksenhendler, L 
Gerard, JM Molina, W Rozenbaum, B Denis, N De Castro, 
C Lascoux), Corevih Ile de France Nord (Paris-Hôpital 
Bichat-Claude Bernard: Y Yazdanpanah, S Matheron, S 
Lariven, V Joly, C Rioux; St Denis-Hôpital Delafontaine: 
MA Khuong-Josses, M Poupard, B Taverne), Corevih Ile 
de France Ouest (Argenteuil-CH Victor Dupouy: L Sutton, 
V Masse, P Genet, B Wifaq, J Gerbe; Boulogne Billancourt-
Hôpital Ambroise Paré: E Rouveix, S Greffe, C Dupont, 
A  Freire Maresca, E Reimann; Colombes-Hôpital Louis 
Mourier: M Bloch, F Meier, E Mortier, F Zeng, B Montoya; 
Garches-Hôpital Raymond Poincaré: C Perronne P de 
Truchis, D Mathez, D Marigot-Outtandy, H Berthé; 
Le Chesnay-Hôpital André Mignot: A  Greder Belan, 
A  Therby, C Godin Collet, S Marque Juillet, M Ruquet, 
S Roussin-Bretagne, P Colardelle; Mantes La Jolie-CH 
François Quesnay: F Granier, JJ Laurichesse, V Perronne; 
Meulan-CHI de Meulan les Mureaux: T Akpan, M 
Marcou; Nanterre-Hôpital Max Fourestier: V Daneluzzi, J 
Gerbe; Poissy-CHI de Poissy: C Veyssier-Belot, H Masson; 
St Germaine en Laye-CHI de St-Germain-en-Laye: Y 
Welker, P Brazille; Suresnes-Hôpital Foch: JE Kahn, D 
Zucman, C Majerholc, E Fourn, D Bornarel), Corevih 
Ile de France Sud (Clamart-Hôpital Antoine Béclère: F 
Boué, S Abgrall, V Chambrin, I Kansau, M Raho-Moussa; 
Créteil-Hôpital Henri Mondor: JD Lelievre, G Melica, M 
Saidani, C Chesnel, C Dumont; Kremlin Bicêtre-Hôpital 
de Bicêtre: D Vittecoq, O Derradji, C Bolliot, C Goujard, E 
Teicher, J Gasnault, M Mole, K Bourdic; Paris-GH Tarnier-
Cochin: D Salmon, C Le Jeunne, O Launay, P Guet, MP 
Pietri, E Pannier Metzger, V Marcou, P Loulergue, N 
Dupin, JP Morini, J Deleuze, P Gerhardt, J Chanal; Paris-
Hôpital Européen Georges Pompidou: L Weiss, J Pavie, Ml 
Lucas, C Jung, M Ptak; Paris-Hôpital Hôtel Dieu: JP Viard, 
J Ghosn, P Gazalet, A  Cros, A  Maignan; Paris-Hôpital 
Necker adultes: C Duvivier, O Lortholary, C Rouzaud, F 
Touam, K Benhadj; Paris-CMIP Pasteur: PH Consigny, P 
Bossi, A Gergely, G Cessot, F Durand).
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Outside Paris area: Corevih Alsace (CH de Mulhouse: G Beck-
Wirth, C Michel, M Benomar; CHRU de Strasbourg: D Rey, M 
Partisani, C Cheneau, ML Batard, P Fischer), Corevih de l’Arc 
Alpin (CHU de Grenoble: P Leclercq, M Blanc, P Morand, O 
Epaulard, A Signori-Schmuck), Corevih Auvergne-Loire (CHU 
de Clermont-Ferrand: H Laurichesse, C Jacomet, M Vidal, D 
Coban, S Casanova; CHRU de Saint-Etienne: A  Fresard, C 
Guglielminotti, E Botelho-Nevers, A  Brunon-Gagneux, V 
Ronat); Corevih Basse-Normandie (CHRU de Caen: R Verdon, 
S Dargère, E Haustraete, P Féret, P Goubin), Corevih Bourgogne 
(CHRU de Dijon: P Chavanet, A Fillion, L Piroth, D Croisier, 
S Gohier), Corevih Bretagne (CHU de Rennes: C Arvieux, F 
Souala, JM Chapplain, M Ratajczak, J Rohan), Corevih Centre 
Poitou-Charentes (CHRU de Tours), Corevih Franche-Comté 
(CH de Belfort: JP Faller, O Ruyer, V Gendrin, L Toko; CHRU 
de Besançon: C Chirouze, L Hustache-Mathieu, JF Faucher, 
A Proust, N Magy-Bertrand, H Gil, N Méaux-Ruault); Corevih 
Haute-Normandie (CHRU de Rouen), Corevih Languedoc-
Roussillon (CHU de Montpellier; CHU de Nîmes: A  Sotto, 
I Rouanet, JM Mauboussin, R Doncesco, G Jacques), Corevih 
Lorraine Champagne Ardennes (Nancy-Hôpital de Brabois: T 
May, C Rabaud, M Andre, M Delestan, MP Bouillon; CHRU de 
Reims: F Bani-Sadr, C Rouger, JL Berger, Y Nguyen), Corevih de 
Midi-Pyrénées Limousin (Toulouse CHU Purpan: B Marchou, 
P Delobel, G Martin Blondel, L Cuzin, N Biezunski, L Alric, D 
Bonnet, M Guivarch, A Palacin, V Payssan), Corevih Nord-Pas 
de Calais (CH de Tourcoing: H Melliez, F Ajana, A Meybeck, 
N Viget), Corevih PACA Est (Nice Hôpital Archet 1: C Pradier, 
P Pugliese, PM Roger, E Rosenthal, J Durant, E Cua, A Naqvi, 
I Perbost, K Risso; CH Antibes-Juan les Pins: D Quinsat; CHI 
de Fréjus/St Raphaël: P Del Giudice; CH de Grasse: PY Dides), 
Corevih PACA Ouest (Marseille-Hôpital de la Conception: P 
Enel, R Sambuc, MS Antolini-Bouvenot, P Druart, L Meddeb, 
I  Ravaux, A  Menard, C Tomei, C Dhiver, H Tissot-Dupont; 
Marseille-Hôpital Nord: J Moreau, S Mokhtari, MJ Soavi, V 
Thomas; Marseille-Hôpital Sainte-Marguerite: I Poizot-Martin, 
S Bregigeon, O Faucher, V Obry-Roguet, AS Ritleng, N Petit; 
Marseille-Centre pénitentiaire des Baumettes: C Bartoli, JM 
Ruiz, D Blanc; CH d’Aix-En-Provence: T Allegre, M Sordage, 
JM Riou, C Faudon; CH d’Avignon: B Slama, H Zerazhi, O 
Boulat, S Chebrek, M Beyrne; CH de Digne Les Bains: P 
Granet Brunello; CH de Gap: L Pellissier, D Bonnabel; CH de 
Martigues: R Cohen Valensi, B Mouchet, G Mboungou; CHI de 
Toulon: A Lafeuillade, E Hope-Rapp, G Hittinger, G Philip, V 
Lambry), Corevih Pays de la Loire (CHU de Nantes: F Raffi, C 
Allavena, E Billaud, N Hall, V Reliquet), Corevih de la Vallée du 
Rhône (Lyon-Hôpital de la Croix-Rousse: C Chidiac, L Cotte, T 
Ferry, T Perpoint, P Miailhes; Lyon-Hôpital Edouard Herriot: 
A Boibieux, JM Livrozet, D Makhloufi, F Brunel, P Chiarello).
Overseas: Corevih Guadeloupe (CHU de Pointe-à-Pitre: 
B Hoen, I Lamaury, I Fabre, K Samar, E Duvallon; CH Saint-
Martin: C Clavel, S Stegmann, V Walter), Corevih Guyane (CH 
de Cayenne: M Nacher, L Adriouch, F Huber, V Vanticlke, P 
Couppié), Corevih Martinique (CHU de Fort-de-France: 
A  Cabié, S Abel, S Pierre-François), Corevih de La Réunion 
(St Denis-CHU Félix Guyon: C Gaud, C Ricaud, R Rodet, G 
Wartel, C Sautron; St Pierre-GH Sud Réunion: P Poubeau, G 
Borgherini, G Camuset).
ClinSurv HIV, Germany:
The clinical surveillance of HIV, ClinSurv HIV, is funded by 
the Robert Koch Institute, which is the German Public Health 
Institute.
Berlin: PD Dr K.  Arastéh, S.  Kowohl Vivantes (Auguste-
Viktoria-Clinic); Dr D.  Schürmann, M.  Warncke Charité, 
University Medicine Berlin; Bonn: Prof. Dr J.  Rockstroh, 
Dr J.  Wasmuth, S.  Hass University Medical Centre Bonn; 
Duesseldorf: PD Dr. B.O. Jensen, C. Feind University Medical 
Centre Düsseldorf; Essen: Dr S.  Esser, P.  Schenk-Westkamp 
University Clinic Essen; Frankfurt: A. Haberl, C. Stephan HIV 
Center J.W.Goethe-University Frankfurt; Hamburg: Prof. Dr 
A. Plettenberg, F. Kuhlendahl ifi (Institute for Interdisciplinary 
Medicine); Drs. A. Adam/ L. Weitner/ K. Schewe, H. Goey, Drs. 
S.  Fenske/ T.  Buhk/ Prof. HJ. Stellbrink/ PD C.  Hoffmann/ S 
Hansen at ICH (Infectious Diseases Centre) Study Centre 
Hamburg Hamburg; PD Dr. O Degen, M. Heuer at University 
Medical Centre Hamburg-Eppendorf; Hannover: Prof. Dr 
M. Stoll, S. Gerschmann at Medical University Hannover; Kiel: 
Prof. Dr H. Horst, S. Trautmann at University Clinic Schleswig-
Holstein; Cologne: Prof Dr G.  Fätkenheuer, D.  Gillor at 
University Medical Centre Cologne; Munich: Prof Dr J. Bogner, 
B.  Sonntag at University Hospital Munich; Regensburg: Prof 
Dr B.  Salzberger at University Medical Centre Regensburg; 
Rostock: Dr C. Fritzsche at University Clinic Rostock.
AMACS, Greece:
The AMACS is a collaborative, open, ongoing, population-based 
cohort study started in 1996, initially supported financially by 
the Hellenic Center for Infectious Diseases Control (HCIDC).
Steering Committee: Antoniadou A., Chrysos G., Daikos 
G., Gargalianos-Kakolyris P., Gogos HA., Katsarou O., Lazanas 
M., Metallidis S., Panagopoulos P., Panos G., Paparizos V., 
Paraskevis D., Sambatakou H., Sipsas N., Skoutelis A., Touloumi 
G. (Chair).
Coordinating Center: Department of Hygiene, Epidemiology 
and Medical Statistics, Athens University Medical School, 
Greece (Touloumi G., Pantazis N., Vourli G., Souliou T., 
Gioukari V.)
Participating Centers: 4th Dept of Internal Medicine, Athens 
Medical School, Attikon University Hospital (Antoniadou 
A, Papadopoulos A, Petrikkos G); Infectious Disease Unit, 
“Tzaneio” General Hospital of Pireaus (Chrysos G, Paraskeva 
D, Hatziastros P); 1st Dept of Propedeutic Medicine, Athens 
University, Medical School “Laikon” General Hopsital (Daikos 
G, Psichogiou M); 1st Dept of Medicine, Infectious Diseases 
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Unit, “G. Gennimatas” Athens General Hospital (Gargalianos-
Kakolyris P, Xylomenos G); 1st Dept of Internal Medicine, 
Infectious Diseases Section, Patras University Hospital (Gogos 
HA, Marangos MN, Panos G); Haemophilia Centre, 2nd 
Blood Transfusion Centre, “Laikon” Athens General Hospital 
(Katsarou O, Kouramba A, Ioannidou P); AIDS Unit, Dept 
of Pathophysiology, “Laikon” Athens General Hospital and 
Athens University, Medical School (Sipsas NV, Kontos A); 
Infectious Diseases Unit, Red Cross General Hospital of Athens 
(Lazanas M, Chini M, Tsogas N); 1st Dept of Internal Medicine, 
Infectious Diseases Devision, AHEPA University Hospital, 
Aristotle University HIV Unit (Metallidis S, Tsachouridou O, 
Skoura L); 2nd Internal Medicine Clinic, 1st IKA (Panos G, 
Haratsis G); AIDS Unit, Clinic of Venereologic & Dermatologic 
Diseases, Athens University, Medical School, Syngros Hospital 
(Paparizos V, Leuow K, Kourkounti S); HIV Unit, 2nd Dpt. 
of Internal Medicine, Athens University, Medical School, 
Hippokration General Hospital (Sambatakou H, Mariolis 
I); Infectious Diseases & HIV Division, Dept of Internal 
Medicine, Evaggelismos Athens General Hospital (Skoutelis 
A, Papastamopoulos V); Infectious Diseases Unit, University 
General Hospital of Alexandroupolis, Democritus University of 
Thrace (Panagopoulos P, Ganitis A).
ICoNA, Italy:
Board of Directors: A  d’Arminio Monforte (President), M 
Andreoni, A Antinori, A Castagna, F Castelli, R Cauda, G Di 
Perri, M Galli, R Iardino, G Ippolito, A Lazzarin, G Marchetti, 
CF Perno, F von Schloesser, P Viale.
Scientific Secretary: A  d’Arminio Monforte, A  Antinori, 
A Castagna, F Ceccherini-Silberstein, A Cozzi-Lepri, E Girardi, 
S Lo Caputo, C Mussini, M Puoti.
Steering Committee: M Andreoni, A  Ammassari, 
A  Antinori, C Balotta, A  Bandera, P Bonfanti, S Bonora, M 
Borderi, A Calcagno, L Calza, MR Capobianchi, A Castagna, F 
Ceccherini-Silberstein, A Cingolani, P Cinque, A Cozzi-Lepri, 
A d’Arminio Monforte, A De Luca, A Di Biagio, E Girardi, N 
Gianotti, A  Gori, G Guaraldi, G Lapadula, M Lichtner, S Lo 
Caputo, G Madeddu, F Maggiolo, G Marchetti, S Marcotullio, 
L Monno, C Mussini, S Nozza, M Puoti, E Quiros Roldan, R 
Rossotti, S Rusconi, MM Santoro, A Saracino, M Zaccarelli.
Statistical And Monitoring Team: A Cozzi-Lepri, I Fanti, L 
Galli, P Lorenzini, A Rodano, M Shanyinde, A Tavelli.
Biological Bank INMI: F Carletti, S Carrara, A  Di Caro, S 
Graziano, F Petrone, G Prota, S Quartu, S Truffa.
Participating Physicians And Centers: A  Giacometti, 
A  Costantini, C Valeriani (Ancona); G Angarano, L Monno, 
C Santoro (Bari); F Maggiolo, C Suardi (Bergamo); P Viale, 
V Donati, G Verucchi (Bologna); F Castelli, E Quiros Roldan, 
C Minardi (Brescia); T Quirino, C Abeli (Busto Arsizio); PE 
Manconi, P Piano (Cagliari); B Cacopardo, B Celesia (Catania); 
J Vecchiet, K Falasca (Chieti); L Sighinolfi, D Segala (Ferrara); F 
Mazzotta, F Vichi (Firenze); G Cassola, C Viscoli, A Alessandrini, 
N Bobbio, G Mazzarello (Genova); C Mastroianni, V Belvisi 
(Latina); P Bonfanti, I  Caramma (Lecco); A  Chiodera, AP 
Castelli (Macerata); M Galli, A Lazzarin, G Rizzardini, M Puoti, 
A  d’Arminio Monforte, AL Ridolfo, R Piolini, A  Castagna, 
S Salpietro, L Carenzi, MC Moioli, C Tincati, G Marchetti 
(Milano); C Mussini, C Puzzolante (Modena); A  Gori, G 
Lapadula (Monza); N Abrescia, A  Chirianni, G Borgia, F Di 
Martino, L Maddaloni, I Gentile, R Orlando (Napoli); F Baldelli, 
D Francisci (Perugia); G Parruti, T Ursini (Pescara); G Magnani, 
MA Ursitti (Reggio Emilia); R Cauda, M Andreoni, A Antinori, 
V Vullo, A Cristaudo, A Cingolani, G Baldin, S Cicalini, L Gallo, 
E Nicastri, R Acinapura, M Capozzi, R Libertone, S Savinelli, 
A Latini, G Iaiani, L Fontanelli Sulekova (Roma); M Cecchetto, 
F Viviani (Rovigo); MS Mura, G Madeddu (Sassari); A De Luca, 
B Rossetti (Siena); P Caramello, G Di Perri, GC Orofino, S 
Bonora, M Sciandra (Torino); M Bassetti, A Londero (Udine); 
G Pellizzer, V Manfrin (Vicenza).
ATHENA, The Netherlands:
The ATHENA database is maintained by Stichting HIV 
Monitoring and supported by a grant from the Dutch Ministry 
of Health, Welfare and Sport through the Centre for Infectious 
Disease Control of the National Institute for Public Health and 
the Environment.
Clinical Centres (*denotes site coordinating physician):
Academic Medical Centre of the University of Amsterdam: HIV 
treating physicians: J.M. Prins*, T.W. Kuijpers, H.J. Scherpbier, 
J.T.M.  van der Meer, F.W.M.N. Wit, M.H. Godfried, P.  Reiss, 
T.  van der Poll, F.J.B. Nellen, S.E. Geerlings, M.  van Vugt, 
D. Pajkrt, W.J. Wiersinga, M. van der Valk, A. Goorhuis, J.W. 
Hovius. HIV nurse consultants: M.A.H. Bijsterveld, J.  van 
Eden, A.M.H.  van Hes, M.  Mutschelknauss, H.E. Nobel, F.J.J. 
Pijnappel, A.M. Weijsenfeld. HIV clinical virologists/chem-
ists: S.  Jurriaans, N.K.T. Back, H.L. Zaaijer, B.  Berkhout, 
M.T.E. Cornelissen, C.J. Schinkel, X.V. Thomas. Admiraal De 
Ruyter Ziekenhuis, Goes: HIV treating physicians: M. van den 
Berge, A.  Stegeman. HIV nurse consultants: S.  Baas, L.  Hage 
de Looff. HIV clinical virologists/chemists: B Wintermans, J 
Veenemans. Catharina Ziekenhuis, Eindhoven: HIV treating 
physicians: M.J.H. Pronk*, H.S.M. Ammerlaan. HIV nurse con-
sultants: E.S. de Munnik, E. van Beek. HIV clinical virologists/
chemists: A.R. Jansz, J.  Tjhie, M.C.A. Wegdam, B.  Deiman, 
V.  Scharnhorst. Elisabeth-TweeSteden Ziekenhuis, Tilburg: 
HIV treating physicians: M.E.E. van Kasteren*, A.E. Brouwer. 
HIV nurse consultants: R.  van Erve, B.A.F.M.  de Kruijf-
van de Wiel, S.Keelan-Pfaf, B.  van der Ven. Data collection: 
B.A.F.M.  de Kruijf-van de Wiel, B.  van der Ven. HIV clinical 
virologists/chemists: A.G.M. Buiting, P.J. Kabel, D.Versteeg. 
Emma Kinderziekenhuis: HIV nurse consultants: A.  van der 
Plas, A.M. Weijsenfeld. Erasmus MC, Rotterdam: HIV treat-
ing physicians: M.E. van der Ende*, H.I. Bax, E.C.M. van Gorp, 
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J.L. Nouwen, B.J.A. Rijnders, C.A.M. Schurink, A.  Verbon, 
T.E.M.S.  de Vries-Sluijs. HIV nurse consultants: N.  Bassant, 
J.E.A. van Beek, M. Vriesde, L.M. van Zonneveld. Data collec-
tion: H.J.  van den Berg-Cameron, F.B. Bruinsma-Broekman, 
J.  de Groot, M.  de Zeeuw-de Man. HIV clinical virologists/
chemists: C.A.B. Boucher, M.P.G Koopmans, J.J.A van Kampen, 
S.D. Pas. Erasmus MC–Sophia, Rotterdam: HIV treating physi-
cians: G.J.A. Driessen, A.M.C. van Rossum. HIV nurse consult-
ants: L.C.  van der Knaap, E.  Visser. Flevoziekenhuis, Almere: 
HIV treating physicians: J.  Branger*, A.  Rijkeboer-Mes. HIV 
nurse consultant and data collection: C.J.H.M. Duijf-van de 
Ven. HagaZiekenhuis, Den Haag: HIV treating physicians: E.F. 
Schippers*, C. van Nieuwkoop. HIV nurse consultants: J.M. van 
IJperen, J. Geilings. Data collection: G. van der Hut. HIV clin-
ical virologist/chemist: P.F.H. Franck. HIV Focus Centrum (DC 
Klinieken): HIV treating physicians: A. van Eeden*. HIV nurse 
consultants: W.  Brokking, M.  Groot, L.J.M. Elsenburg. HIV 
clinical virologists/chemists: M. Damen, I.S. Kwa. Isala, Zwolle: 
HIV treating physicians: P.H.P. Groeneveld*, J.W. Bouwhuis. 
HIV nurse consultants: J.F. van den Berg, A.G.W. van Hulzen. 
Data collection: G.L.  van der Bliek, P.C.J. Bor. HIV clinical 
virologists/chemists: P.  Bloembergen, M.J.H.M. Wolfhagen, 
G.J.H.M. Ruijs. Leids Universitair Medisch Centrum, 
Leiden: HIV treating physicians: F.P. Kroon*, M.G.J.  de Boer, 
H. Jolink, A.M. Vollaard. HIV nurse consultants: W. Dorama, 
N. van Holten. HIV clinical virologists/chemists: E.C.J. Claas, 
E.  Wessels. Maasstad Ziekenhuis, Rotterdam: HIV treating 
physicians: J.G. den Hollander*, K. Pogany, A. Roukens. HIV 
nurse consultants: M. Kastelijns, J.V. Smit, E. Smit, D. Struik-
Kalkman, C.  Tearno. Data collection: M.  Bezemer, T.  van 
Niekerk. HIV clinical virologists/chemists: O.  Pontesilli. 
Maastricht UMC+, Maastricht: HIV treating physicians: S.H. 
Lowe*, A.M.L. Oude Lashof, D.  Posthouwer. HIV nurse con-
sultants: R.P. Ackens, J. Schippers, R. Vergoossen. Data collec-
tion: B.  Weijenberg-Maes. HIV clinical virologists/chemists: 
I.H.M.  van Loo, T.R.A. Havenith. MCH-Bronovo, Den Haag: 
HIV treating physicians: E.M.S. Leyten*, L.B.S. Gelinck. HIV 
nurse consultants: A.Y.  van Hartingsveld, C.  Meerkerk, G.S. 
Wildenbeest. HIV clinical virologists/chemists: J.A.E.M. 
Mutsaers, S.Q.  van Veen. MC Slotervaart, Amsterdam: HIV 
treating physicians: J.W. Mulder*, S.M.E. Vrouenraets, F.N. 
Lauw. HIV nurse consultants: M.C. van Broekhuizen, H. Paap, 
D.J. Vlasblom. HIV clinical virologists/chemists: P.H.M. Smits. 
MC Zuiderzee, Lelystad: HIV treating physicians: S.  Weijer*, 
R. El Moussaoui. HIV nurse consultant: A.S. Bosma. Medisch 
Centrum Leeuwarden, Leeuwarden: HIV treating physicians: 
M.G.A.van Vonderen*, D.P.F.  van Houte, L.M. Kampschreur. 
HIV nurse consultants: K. Dijkstra, S. Faber. HIV clinical virol-
ogists/chemists: J Weel. Medisch Spectrum Twente, Enschede: 
HIV treating physicians: G.J. Kootstra*, C.E. Delsing. HIV 
nurse consultants: M. van der Burg-van de Plas, H. Heins. Data 
collection: E.  Lucas. Noordwest Ziekenhuisgroep, Alkmaar: 
HIV treating physicians: W.  Kortmann*, G.  van Twillert*, 
J.W.T. Cohen Stuart, B.M.W. Diederen, R.  Renckens. HIV 
nurse consultant and data collection: D. Ruiter-Pronk, F.A. van 
Truijen-Oud. HIV clinical virologists/chemists: W. A. van der 
Reijden, R.  Jansen. OLVG, Amsterdam: HIV treating physi-
cians: K.  Brinkman*, G.E.L.  van den Berk, W.L. Blok, P.H.J. 
Frissen, K.D. Lettinga W.E.M. Schouten, J.  Veenstra. HIV 
nurse consultants: C.J. Brouwer, G.F. Geerders, K. Hoeksema, 
M.J. Kleene, I.B.  van der Meché, M.  Spelbrink, H.  Sulman, 
A.J.M. Toonen, S.  Wijnands. HIV clinical virologists: 
M.  Damen, D.  Kwa. Data collection: E.  Witte. Radboudumc, 
Nijmegen: HIV treating physicians: R. van Crevel*, M. Keuter, 
A.J.A.M. van der Ven, H.J.M. ter Hofstede, A.S.M. Dofferhoff. 
HIV nurse consultants: M.  Albers, K.J.T. Grintjes-Huisman, 
M. Marneef, A. Hairwassers. HIV clinical virologists/chemists: 
J.  Rahamat-Langendoen. HIV clinical pharmacology consult-
ant: D.  Burger. Rijnstate, Arnhem: HIV treating physicians: 
E.H. Gisolf*, R.J. Hassing, M.  Claassen. HIV nurse consult-
ants: G.  ter Beest, P.H.M.  van Bentum, N.  Langebeek. HIV 
clinical virologists/chemists: R.  Tiemessen, C.M.A. Swanink. 
Spaarne Gasthuis, Haarlem: HIV treating physicians: S.F.L. van 
Lelyveld*, R.  Soetekouw. HIV nurse consultants: L.M.M.  van 
der Prijt, J. van der Swaluw. Data collection: N. Bermon. HIV 
clinical virologists/chemists: W.A. van der Reijden, R.  Jansen, 
B.L. Herpers, D.Veenendaal. Medisch Centrum Jan van Goyen, 
Amsterdam: HIV treating physicians: D.W.M. Verhagen. 
HIV nurse consultants: M.  van Wijk. Universitair Medisch 
Centrum Groningen, Groningen: HIV treating physicians: 
W.F.W. Bierman*, M.  Bakker, J.  Kleinnijenhuis, E.  Kloeze, 
H.  Scholvinck, Y.  Stienstra, C.L. Vermont, K.R. Wilting. HIV 
nurse consultants: A. Boonstra, H. de Groot-de Jonge, P.A. van 
der Meulen, D.A. de Weerd. HIV clinical virologists/chemists: 
H.G.M. Niesters, C.C. van Leer-Buter, M. Knoester. Universitair 
Medisch Centrum Utrecht, Utrecht: HIV treating physicians: 
A.I.M. Hoepelman*, J.E. Arends, R.E. Barth, A.H.W. Bruns, 
P.M. Ellerbroek, T.  Mudrikova, J.J. Oosterheert, E.M. Schadd, 
M.W.M. Wassenberg, M.A.D.  van Zoelen. HIV nurse con-
sultants: K.  Aarsman, D.H.M.  van Elst-Laurijssen, E.E.B.  van 
Oers-Hazelzet. Data collection: M.  van Berkel. HIV clinical 
virologists/chemists: R.  Schuurman, F.  Verduyn-Lunel, A.M.J. 
Wensing. VUmc, Amsterdam: HIV treating physicians: E.J.G. 
Peters*, M.A. van Agtmael, M. Bomers, J. de Vocht. HIV nurse 
consultants: M. Heitmuller, L.M. Laan. HIV clinical virologists/
chemists: C.W. Ang, R.  van Houdt, A.M. Pettersson, C.M.J.E. 
Vandenbroucke-Grauls. Wilhelmina Kinderziekenhuis, 
UMCU, Utrecht: HIV treating physicians: S.P.M. Geelen, T.F.W. 
Wolfs, L.J. Bont. HIV nurse consultants: N. Nauta.
Coordinating Centre
Director: P. Reiss. Data analysis: D.O. Bezemer, A.I. van Sighem, 
C.  Smit, F.W.M.N. Wit, T.S. Boender. Data management and 
quality control: S. Zaheri, M. Hillebregt, A. de Jong. Data mon-
itoring: D.  Bergsma, A.  de Lang, S.  Grivell, A.  Jansen, M.J. 
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Rademaker, M.  Raethke, R.  Meijering, S.  Schnörr. Data col-
lection: L. de Groot, M. van den Akker, Y. Bakker, E. Claessen, 
A. El Berkaoui, J. Koops, E. Kruijne, C. Lodewijk, L. Munjishvili, 
B. Peeck, C. Ree, R. Regtop, Y. Ruijs, T. Rutkens, L. van de Sande, 
M. Schoorl, A. Timmerman, E. Tuijn, L. Veenenberg, S. van der 
Vliet, A. Wisse, T. Woudstra. Patient registration: B. Tuk.
CoRIS, Spain:
This work was supported by the Spanish Network of HIV/AIDS 
(RD12/0017/0018) and CIBER Epidemiología y Salud Pública 
(CIBERESP), Spain. J.  del Amo, V.  Hernando, A.  Diaz: This 
article presents independent results and research. The views 
expressed are those of the authors and not necessarily those of 
the Instituto de Salud Carlos III.
Centers and investigators involved in CoRIS: Executive 
committee: Santiago Moreno, Julia del Amo, David Dalmau, 
Maria Luisa Navarro, Maria Isabel González, Jose Luis Blanco, 
Federico Garcia, Rafael Rubio, Jose Antonio Iribarren, Félix 
Gutiérrez, Francesc Vidal, Juan Berenguer, Juan González. 
Fieldwork, data management and analysis: Paz Sobrino, 
Victoria Hernando, Belén Alejos, Débora Álvarez, Inma 
Jarrín, Cristina Moreno. BioBanK HIV: M Ángeles Muñoz-
Fernández, Isabel García-Merino, Coral Gómez Rico, Jorge 
Gallego de la Fuente y Almudena García Torre. Participating 
centres: Hospital General Universitario de Alicante (Alicante): 
Joaquín Portilla, Esperanza Merino, Sergio Reus, Vicente Boix, 
Livia Giner, Carmen Gadea, Irene Portilla, Maria Pampliega, 
Marcos Díez, Juan Carlos Rodríguez, Jose Sánchez-Payá. 
Hospital Universitari de Bellvitge (Hospitalet de Llobregat): 
Daniel Podzamczer, Elena Ferrerm Arkaitz Imaz, Evan Van 
Den Eyncle, Silvana Di Yacovo, Maria Sumoy. Hospital 
Universitario de Canarias (Santa Cruz de Tenerife): Juan Luis 
Gómez, Jehovana Hernández, María Remedios Alemán, María 
del Mar Alonso, María Inmaculada Hernández, Felicitas Díaz-
Flores, Dácil García, Ricardo Pelazas. Hospital Universitario 
Central de Asturias (Oviedo): Victor Asensi, Eulalia Valle, 
José Antonio Cartón. Hospital Clínico San Carlos (Madrid): 
Vicente Estrada Pérez, Maria Jesus Téllez Molina, Jorge Vergas 
García, Elisa Pérez-Cecila Carrera. Hospital Doce de Octubre 
(Madrid): Rafael Rubio, Federico Pulido, Otilia Bisbal, 
Mariano Matarranz, Maria Lagarde, Rafael Rubio-Martín, 
Asunción Hernando, Laura Bermejo y Lourdes Dominguez. 
Hospital Universitario Donostia (San Sebastián): José Antonio 
Iribarren, Julio Arrizabalaga, María José Aramburu, Xabier 
Camino, Francisco Rodríguez-Arrondo, Miguel Ángel von 
Wichmann, Lidia Pascual Tomé, Miguel Ángel Goenaga, 
Mª Jesús Bustinduy, Harkaitz Azkune Galparsoro. Maialen 
Ibarguren, Mirian Aguado, Maitane Umerez. Hospital General 
Universitario de Elche (Elche): Félix Gutiérrez, Mar Masiá, 
Cristina López, Sergio Padilla, Andrés Navarro, Fernando 
Montolio, Catalina Robledano, Joan Gregori Colomé, Araceli 
Adsuar, Rafael Pascual, Federico Carlos, Maravillas Martinez, 
Jara Llenas García, Marta Fernández, Elena García. Hospital 
Germans Trías i Pujol (Badalona): Roberto Muga, Jordi Tor, 
Arantza Sanvisens. Hospital General Universitario Gregorio 
Marañón (Madrid): Juan Berenguer, Juan Carlos López 
Bernaldo de Quirós, Pilar Miralles, Isabel Gutiérrez, Margarita 
Ramírez, Belén Padilla, Paloma Gijón, Ana Carrero, Teresa 
Aldamiz-Echevarría, Francisco Tejerina, Francisco Jose Parras, 
Pascual Balsalobre, Cristina Diez. Hospital Universitari de 
Tarragona Joan XXIII, IISPV, Universitat Rovira i Virgili 
(Tarragona): Francesc Vidal, Joaquín Peraire, Consuelo 
Viladés, Sergio Veloso, Montserrat Vargas, Miguel López-
Dupla, Montserrat Olona, Alba Aguilar, Joan Josep Sirvent, 
Verónica Alba, Olga Calavia. Hospital Universitario La Fe 
(Valencia): Marta Montero, José Lacruz, Marino Blanes, Eva 
Calabuig, Sandra Cuellar, José López, Miguel Salavert. Hospital 
Universitario La Paz/IdiPaz (Madrid): Juan González, Ignacio 
Bernardino de la Serna, José Ramón Arribas, María Luisa 
Montes, Jose Mª Peña, Blanca Arribas, Juan Miguel Castro, Fco 
Javier Zamora, Ignacio Pérez, Miriam Estébanez, Silvia García, 
Marta Díaz, Natalia Stella Alcáriz, Jesús Mingorance, Dolores 
Montero, Alicia González, Maria Isabel de José. Hospital de la 
Princesa (Madrid): Ignacio de los Santos, Jesús Sanz, Ana Salas, 
Cristina Sarriá, Ana Gómez Berrocal, Lucio Garcia-Fraile. 
Hospital San Pedro-CIBIR (Logroño): José Antonio Oteo, José 
Ramón Blanco, Valvanera Ibarra, Luis Metola, Mercedes Sanz, 
Laura Pérez-Martínez. Hospital Universitario Miguel Servet 
(Zaragoza): Ascensión Pascual, Carlos Ramos, Piedad Arazo, 
Desiré Gil. Hospital Universitari Mutua de Terrassa (Terrassa): 
David Dalmau, Angels Jaén, Mireia Cairó, Daniel Irigoyen, 
Queralt Jordano, Mariona Xercavins, Javier Martinez-Lacasa, 
Pablo Velli, Roser Font, Montse Sanmartí, Laura Ibáñez. 
Complejo Hospitalario de Navarra (Pamplona): María Rivero, 
Marina Itziar Casado, Jorge Alberto Díaz, Javier Uriz, Jesús 
Repáraz, Carmen Irigoyen, María Jesús Arraiza. Hospital Parc 
Taulí (Sabadell): Ferrán Segura, María José Amengual, Gemma 
Navarro, Montserrat Sala, Manuel Cervantes, Valentín Pineda, 
Victor Segura, Marta Navarro, Esperanza Antón, Mª Merce 
Nogueras. Hospital Ramón y Cajal (Madrid): Santiago Moreno, 
José Luis Casado, Fernando Dronda, Ana Moreno, María 
Jesús Pérez Elías, Dolores López, Carolina Gutiérrez, Nadia 
Madrid, Angel Lamas, Paloma Martí, Alberto de Diaz, Sergio 
Serrrano, Lucas Donat. Hospital Reina Sofía (Murcia): Alfredo 
Cano, Enrique Bernal, Ángeles Muñoz. Hospital San Cecilio 
(Granada): Federico García, José Hernández, Alejandro Peña, 
Leopoldo Muñoz, Jorge Parra, Marta Alvarez, Natalia Chueca, 
Vicente Guillot, David Vinuesa, Jose Angel Fernández. Centro 
Sanitario Sandoval (Madrid): Jorge Del Romero, Carmen 
Rodríguez, Teresa Puerta, Juan Carlos Carrió, Mar Vera, Juan 
Ballesteros. Hospital de la Santa Creu i Sant Pau (Barcelona): 
Pere Domingo, Mª Antonia Sambeat, Karuna Lamarca, Gracia 
Mateo, Mar Gutiérrez, Irene Fernández. Hospital Universitario 
Santiago de Compostela (Santiago de Compostela): Antonio 
1656 • CID 2017:64 (15 June) • Gourlay et al
Antela, Elena Losada. Hospital Son Espases (Palma de 
Mallorca): Melchor Riera, Maria Peñaranda, Maria Leyes, Mª 
Angels Ribas, Antoni A  Campins, Carmen Vidal, Leire Gil, 
Francisco Fanjul, Carmen Marinescu. Hospital Universitari 
Vall d´Hebron (Barcelona): Esteban Ribera. Hospital Virgen 
de la Victoria (Málaga): Jesús Santos, Manuel Márquez, 
Isabel Viciana, Rosario Palacios, Isabel Pérez, Carmen Maria 
González. Hospital Universitario Virgen del Rocío (Sevilla): 
Pompeyo Viciana, Manuel Leal, Luis Fernando López-Cortés, 
Nuria Espinosa. Hospital Universitario de Basurto (Bilbao): 
Josefa Muñoz, Miren Zuriñe Zubero, Josu Mirena Baraia-
Etxaburu, Sofía Ibarra, Oscar Ferrero, Josefina López de 
Munain, Mª Mar Cámara. Iñigo López, Mireia de la Peña. 
Hospital Universitario Infanta Sofía (San Sebastián de los 
Reyes): Inés Suárez-García, Eduardo Malmierca. Hospital 
Universitario Costa del Sol (Marbella): Julián Olalla, Alfonso 
del Arco, Javier de la torre, José Luis Prada, Zaira Caracuel. 
Hospital del Poniente (El Ejido): Ana Maria Lopez-Lirola, 
Ana Belén Lozano, Elisa Fernández, Inés Pérez, Juan Manuel 
Fernández. Hospital Universitario Santa Lucia (Cartagena): 
Onofre Juan Martínez, Francisco Jesús Vera, Lorena 
Martínez, Josefina García, Begoña Alcaraz, Amaya Jimeno. 
INIBIC-Complejo Hospitalario Universitario de A  Coruña 
(A Coruña): Eva Poveda, Berta Pernas, Álvaro Mena, Marta 
Grandal, Ángeles Castro, José D.  Pedreira. Hospital Clínico 
Universitario Virgen de la Arrixaca (Murcia): Carlos Galera, 
Helena Albendin, Asunción Iborra, Antonio Moreno, Maria 
Angeles Campillo, Asunción Vidal. Hospital Marina Baixa 
(Villajoyosa): Concha Amador, Francisco Pasquau, Javier Ena, 
Concha Benito, Vicenta Fenoll. Complejo Hospitalario de Jaén 
(Jaén): Mohamed Omar Mohamed-Balghata, Maria Amparo 
Gómez. Hospital San Agustín de Aviles (Avilés): Miguel 
Alberto de Zarraga, Maria Eugenia Rivas. Fundación Jiménez 
Diaz (Madrid): Miguel Górgolas.
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